gp160

gp160

a glycoprotein found on the outer surface, or envelope, of the human immunodeficiency virus. It is composed of gp120, which protrudes from the envelope, and gp41, which is embedded in the envelope.
References in periodicals archive ?
Pathogenic significance of alpha-N-acetylgalactosamine activity found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1.
Drugs profiles discussed in this report includes AGS-67E, alemtuzumab, Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia, BMS-906024, Cell Therapy to Target CD38 for cancer, IDD-003, INA-01, lenalidomide, MMIG-202, mogamulizumab, Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease, Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia, NK-314, Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia, PCI-34051, PF-03084014, SL-101, Synthetic Peptide for Oncology and Male health, THV-02, TP-0903.
040 4+ ID Western blot results Remarks n=171 P55 P66 gP120 gP160 gP36 HIV-1 1 1+ 3+ 1+ 1+ Positive 2 3 1+ 3+ 1+ 1+ Positive 4 5 6 3+ 1+ 1+ Positive 7 1+ 4+ 1+ Positive 8 9 10 11 12 1+ 3+ 1+ 1+ Positive 13 1+=Weak positive; 2+=Moderate positive; 3+ and 4+=Strong positive; 8 out of 13 patients were first ELISA positive and second one negative; 5 patients were both ELISA positive and confirmed in western blot for HIV-1.
In particular, the HIV envelope spike, called gp160, is the site of a host of mutations that obstruct the few elements that all of the virus strains share.
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial.
generation Oral fluids Plasma/Blood Viral Lysate and Bio-Rad Yes spot E-coli Laboratories recombinant antigen Third Serum/Plasma Recombinant HIV-1 Abbott Yes generation env and gag Laboratories HIV-2 env proteins Serum/Plasma Purified gp160, Bio-Rad Yes p24, and Laboratories peptides representing regions of gp41 from HIV-1 group 0 and gp36 from HIV-2 Fourth Serum/Plasma HIV-1 gp160, p24 bioMerieux No generation antigen, and Inc.
During the life cycle of HIV, the gp160 precursor protein is cleaved to form:
An EIA for HIV was positive, and a Western blot was positive with bands present for p24, gp40, p55, and gp160.
Protease inhibitors prevent the cleavage of gp160 into gp41 and gp120.
Repeat HIV serologic testing showed a positive HIV enzyme immunoassay and a positive Western blot with bands at gp120, gp160, and p24.
Initially, the group created intrabodies that fuse to gp160, a precursor of the protein that makes up HIV's outer envelope.
It sells proteins including HIV antigens (P24, GP160, GP120, P66 and P55) to the research market.